Grant: Proof of Principle Program - Phase II
McGill University
$293,133.00
Development of novel OXE receptor antagonists for asthma
FY 2013-14
Summary
5-Oxo-ETE is a fatty acid formed from arachidonic acid, an abundant omega-6-polyunsaturated fatty acid. It is a potent activator of eosinophils, a type of white blood cell that accumulates in the lungs in asthma and causes damage due to the release of its toxic constituents, the normal function of which is to kill invading parasites. 5-Oxo-ETE attracts eosinophils and when it is injected into the skin in humans, it causes these cells to migrate from the blood to the site of injection. We hypothesize that 5-oxo-ETE has a deleterious role in promoting eosinophil accumulation in the lungs in asthma, and that if these effects are blocked, asthma symptoms will be alleviated. The effects of 5-oxo-ETE are due to its interaction with the OXE receptor. Many drugs act by binding to receptors, but none are available to prevent the activation of the OXE receptor. We have prepared two novel highly potent OXE receptor antagonists that block the activation of the OXE receptor by 5-oxo-ETE and thereby prevent its actions on isolated eosinophils. The next step will be to determine whether these antagonists are active in animal models of asthma. Unfortunately we cannot use mice or rats because they do not have the OXE receptor. In contrast, monkeys have an OXE receptor that is nearly identical to the one in humans. Because of the increased cost of working with this primate model of human disease we are requesting funds to allow us to determine whether our OXE receptor antagonists can block the induction of asthma-like symptoms provoked by exposure of monkeys to an allergen. These OXE receptor antagonists are the first of their kind to be tested in live animals and could play an important therapeutic role in asthma and other allergic disorders in which eosinophils are prominent. Many asthmatics do not respond well to current medication and there is an urgent need for additional therapeutic approaches such as this, as the number of affected individuals is increasing from year to year.
Department
Program
Proof of Principle Program - Phase II
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
293915
Name
Powell William S
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
AmorChem (Montreal, QC); AmorChem (Montreal, QC)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development of novel OXE receptor antagonists for asthma
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$293,133
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase II
Keyworddelim
5-Lipoxygenase Pathway; Airways; Allergy; Antagonists; Asthma; Eicosanoids; Eosinophils; Inflammation`; Lungs; Primates
Abstract
5-Oxo-ETE is a fatty acid formed from arachidonic acid, an abundant omega-6-polyunsaturated fatty acid. It is a potent activator of eosinophils, a type of white blood cell that accumulates in the lungs in asthma and causes damage due to the release of its toxic constituents, the normal function of which is to kill invading parasites. 5-Oxo-ETE attracts eosinophils and when it is injected into the skin in humans, it causes these cells to migrate from the blood to the site of injection. We hypothesize that 5-oxo-ETE has a deleterious role in promoting eosinophil accumulation in the lungs in asthma, and that if these effects are blocked, asthma symptoms will be alleviated. The effects of 5-oxo-ETE are due to its interaction with the OXE receptor. Many drugs act by binding to receptors, but none are available to prevent the activation of the OXE receptor. We have prepared two novel highly potent OXE receptor antagonists that block the activation of the OXE receptor by 5-oxo-ETE and thereby prevent its actions on isolated eosinophils. The next step will be to determine whether these antagonists are active in animal models of asthma. Unfortunately we cannot use mice or rats because they do not have the OXE receptor. In contrast, monkeys have an OXE receptor that is nearly identical to the one in humans. Because of the increased cost of working with this primate model of human disease we are requesting funds to allow us to determine whether our OXE receptor antagonists can block the induction of asthma-like symptoms provoked by exposure of monkeys to an allergen. These OXE receptor antagonists are the first of their kind to be tested in live animals and could play an important therapeutic role in asthma and other allergic disorders in which eosinophils are prominent. Many asthmatics do not respond well to current medication and there is an urgent need for additional therapeutic approaches such as this, as the number of affected individuals is increasing from year to year.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Powell, William S
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $293,133~ $0~